Gapping down
In reaction to earnings/guidance:
- BEAM -6.4%, VTRS -3.7% (also provided EpiPen settlement information), XRAY -1.2%,
M&A news:
- HR -9.2% (and Healthcare Trust of America (HTA) enter into $18 billion strategic combination), HTA -4.4% (and Healthcare Realty Trust (HR) enter into $18 billion strategic combination), BRO -2% (to acquire Orchid Underwriters Agency and CrossCover Insurance Services; transaction is expected to close before April 2022)
Other news:
- RSX -24.7% (Russia's Central Bank increased rates to 20% from 9.5%; announces additional reserves releases )
- OZON -19% (provides update regarding developments at Ozon Bank)
- CANO -8.9% (will delay its fourth quarter earnings release, conference call and 2022 guidance updates)
- LXRX -8.8% (voluntary withdraws and plans near-term resubmission of the its NDA for sotagliflozin to correct a technical issue)
- BP -7.5% (will exit its shareholding in Rosneft (OJSCY)
- BP has held a 19.75% shareholding in Rosneft since 2013)
- AER -6.9% (signs lease agreements with Norwegian Air Shuttle ASA for ten new Boeing 737 MAX 8 (BA) aircraft and eight Boeing 737-800 NG aircraft )
- TTE -6% (wins maritime lease to develop a 3 GW+ offshore wind farm on the East Coast of New York and New Jersey)
- RETA -3.7% (FDA issues letter re NDA for bardoxolone methyl, FDA says it does not believe the data demonstrates that bardoxolone is effective in slowing the loss of kidney function)
- CRH -3.6% (KPS Capital Partners to acquire Oldcastle Buildingenvelope from the Co)
- EWU -1.8% (UK Government sanctions Russian President Vladimir Putin and Foreign Minister Sergey Lavrov )
- LAC -1.6% (submitted a draft application for funding to be used at its 100%-owned Thacker Pass lithium project in Humboldt County, Nevada)
- UAA -1.5% (files mixed securities shelf offering)
Analyst comments:
- EPAM -4.3% (downgraded to Neutral from Overweight at Piper Sandler)
- FL -3.2% (downgraded to Sell from Buy at Citigroup and downgraded to Underweight from Equal-Weight at Morgan Stanley)
- QRTEA -2% (downgraded to Neutral from Buy at BofA )
- ABBV -1.5% (downgraded to Neutral from Buy at UBS)
- GILD -1.2% (downgraded to Market Perform from Outperform at BMO),